AMP Workshop: From Data to Decisions - Advocating for DPYD Testing to Advance Patient Safety Based on Insights from Clinical Evidence

Guideline-Driven PGx Testing: A New, Targeted Testing Approach Covering AMP Tier 1 and Tier 2 Pharmacogenomic Recommendations

Wednesday, November 20, 2024 | 3:00 - 3:50 PM PST
Room #114-115, Level 1

Add to Your Calendar

Pharmacogenomics is evolving, and so should your testing approach. Join us for this AMP 2024 workshop on standardized pharmacogenomic testing, featuring two renowned experts, Dr. Chad Bousman, Associate Professor, University of Calgary and Dr. Vicky Pratt, Past President of AMP.

Why Attend? Learn about:

The new VeriDose^® Core v2.0 PGx Panel
Implementation of AMP guidelines in your lab
Standardization of PGx testing
Evidence-based testing approaches

An AMP Annual Meeting badge or Corporate Workshop Day badge is needed to attend the workshop.

PRESENTED BY:

Chad Bousman, PhD, Associate Professor, Department of Medical Genetics, University of Calgary

Dr. Bousman is an Associate Professor in the Department of Medical Genetics at the University of Calgary, where he leads the Psychiatric Pharmacogenomics Laboratory. His program of research spans pharmacogenomic discovery and clinical implementation, with particular attention given to improving prescribing for mental health conditions across life stages. Dr. Bousman has published over 200 peer-reviewed papers and his research is supported by Canadian, US, and Australian funding bodies. He is a member of the American College of of Neuropsychopharmacology, Clinical Pharmacogenetics Implementation Consortium (CPIC), Pharmacogene Variation (PharmVar) Consortium, Pharmacogenomics Global Research Network (PGRN), and the Standardized Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative. He is also the founder and CEO of Sequence2Script Inc, a software company that assists laboratories with translating pharmacogenomic information into clinical action.

Victoria M. Pratt, PhD, FACMG, Director of Scientific Affairs for Pharmacogenetics, Agena Bioscience

Dr. Pratt is the Past President of the Association for Molecular Pathology. Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM Genetic Testing Reference Materials Program, the National Academy of Medicine’s Roundtable on Genomics and Precision Health, and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory Committee.

Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine. Her fellowship training was in Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

Pharmacogenetics Workshop

Why Attend? Learn about:

Sign Up for the Replay

About Agena Bioscience

Connect